Last reviewed · How we verify
Trivalent influenza vaccine GSK 138842A
Trivalent influenza vaccine GSK 138842A is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | Trivalent influenza vaccine GSK 138842A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trivalent influenza vaccine GSK 138842A CI brief — competitive landscape report
- Trivalent influenza vaccine GSK 138842A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Trivalent influenza vaccine GSK 138842A
What is Trivalent influenza vaccine GSK 138842A?
Trivalent influenza vaccine GSK 138842A is a Biologic drug developed by GlaxoSmithKline.
Who makes Trivalent influenza vaccine GSK 138842A?
Trivalent influenza vaccine GSK 138842A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Trivalent influenza vaccine GSK 138842A in?
Trivalent influenza vaccine GSK 138842A is in Phase 1.